FORMICA, FRANCESCA
FORMICA, FRANCESCA
Hacking pancreatic cancer: Present and future of personalized medicine
2021 Di Federico A.; Tateo V.; Parisi C.; Formica F.; Carloni R.; Frega G.; Rizzo A.; Ricci D.; Di Marco M.; Palloni A.; Brandi G.
CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors
2020 Dall'Olio F.G.; Abbati F.; Facchinetti F.; Massucci M.; Melotti B.; Squadrilli A.; Buti S.; Formica F.; Tiseo M.; Ardizzoni A.
Long-term survival of two patients with recurrent pancreatic acinar cell carcinoma treated with radiofrequency ablation: A case report.
2020 Di Marco M, Carloni R, De Lorenzo S, Grassi E, Palloni A, Formica F, Brocchi S, Filippini DM, Golfieri R, Brandi G.
Mutational burden of resectable pancreatic cancer by whole-transcriptome and whole-exome sequencing could predict a poor prognosis
2018 Grassi, Elisa; Durante, Sandra; Astolfi, Annalisa; Tarantino, Giuseppe; Indio, Valentina; Freier, Eva; Casadei, Riccardo; Ricci, Claudio; Comito, Francesca; Filippini, Daria; Formica, Francesca; Serra, Carla; Santini, Donatella; D'Errico, Antonietta; Minni, Francesco; Biasco, Guido; Di Marco, Mariacristina
Mutational burden of resectable pancreatic cancer, as determined by whole transcriptome and whole exome sequencing, predicts a poor prognosis.
2018 Grassi E, Durante S, Astolfi A, Tarantino G, Indio V, Freier E, Vecchiarelli S, Ricci C, Casadei R, Formica F, Filippini D, Comito F, Serra C, Santini D, D' Errico A, Minni F, Biasco G, Di Marco M
Higher number of known pancreatic cancer mutations highlighted by whole-transcripto- me and whole-exome sequencing predicts cli- nical outcome in early stage patients
2017 Elisa Grassi, Sandra Durante, Annalisa Astolfi, Giuseppe Tarantino, Valentina Indio, Eva Freier, Francesca Formica, Daria Filippini, Claudio Ricci, Riccardo Casadei, Carla Serra, Donatella Santini, Antonietta D’Errico, Antonio D Pinna, Francesco Minni, Guido Biasco, Mariacristina Di Marco